Cargando…

2D-QSAR Modeling and Molecular Docking Studies on 1H-Pyrazole-1-carbothioamide Derivatives as EGFR Kinase Inhibitors

[Image: see text] Epidermal growth factor receptor (EGFR) kinase has been commonly associated with cancers such as lung, ovarian, hormone-refractory prostate, metastatic colorectal, glioblastoma, pancreatic, and breast cancers. A series of 1H-pyrazole-1-carbothioamide derivatives and their EGFR inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajalsiddig, Tawassl T. H., Osman, Abu Baker M., Saeed, Ahmed E. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407542/
https://www.ncbi.nlm.nih.gov/pubmed/32775868
http://dx.doi.org/10.1021/acsomega.0c01323
_version_ 1783567645356851200
author Hajalsiddig, Tawassl T. H.
Osman, Abu Baker M.
Saeed, Ahmed E. M.
author_facet Hajalsiddig, Tawassl T. H.
Osman, Abu Baker M.
Saeed, Ahmed E. M.
author_sort Hajalsiddig, Tawassl T. H.
collection PubMed
description [Image: see text] Epidermal growth factor receptor (EGFR) kinase has been commonly associated with cancers such as lung, ovarian, hormone-refractory prostate, metastatic colorectal, glioblastoma, pancreatic, and breast cancers. A series of 1H-pyrazole-1-carbothioamide derivatives and their EGFR inhibitory activities were subjected to two-dimensional (2D) quantitative structure–activity relationship (2D-QSAR) studies. The 2D-QSAR models were constructed based on a forward selection of partial least-squares (PLS) and stepwise multiple linear regression (SW-MLR) methods validated by leave-one-out (LOO) and external test set prediction approaches. The stepwise multiple linear regression (SW-MLR) method presented an encouraging result as compared to other methods. The results of the study indicated that the activity of 1H-pyrazole-1-carbothioamide derivatives as an EGFR kinase inhibitor was more influenced by adjacency distance matrix descriptors. The models were improved after outlier removal through the applicability domain. Based on the resultant models, 11 new compounds with high potency were designed as EGFR kinase inhibitors. Molecular docking studies were performed for designing compounds, and they were compared with erlotinib as a reference to predict their interactions in the active site and identify structural features necessary for producing biological activities.
format Online
Article
Text
id pubmed-7407542
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-74075422020-08-07 2D-QSAR Modeling and Molecular Docking Studies on 1H-Pyrazole-1-carbothioamide Derivatives as EGFR Kinase Inhibitors Hajalsiddig, Tawassl T. H. Osman, Abu Baker M. Saeed, Ahmed E. M. ACS Omega [Image: see text] Epidermal growth factor receptor (EGFR) kinase has been commonly associated with cancers such as lung, ovarian, hormone-refractory prostate, metastatic colorectal, glioblastoma, pancreatic, and breast cancers. A series of 1H-pyrazole-1-carbothioamide derivatives and their EGFR inhibitory activities were subjected to two-dimensional (2D) quantitative structure–activity relationship (2D-QSAR) studies. The 2D-QSAR models were constructed based on a forward selection of partial least-squares (PLS) and stepwise multiple linear regression (SW-MLR) methods validated by leave-one-out (LOO) and external test set prediction approaches. The stepwise multiple linear regression (SW-MLR) method presented an encouraging result as compared to other methods. The results of the study indicated that the activity of 1H-pyrazole-1-carbothioamide derivatives as an EGFR kinase inhibitor was more influenced by adjacency distance matrix descriptors. The models were improved after outlier removal through the applicability domain. Based on the resultant models, 11 new compounds with high potency were designed as EGFR kinase inhibitors. Molecular docking studies were performed for designing compounds, and they were compared with erlotinib as a reference to predict their interactions in the active site and identify structural features necessary for producing biological activities. American Chemical Society 2020-07-24 /pmc/articles/PMC7407542/ /pubmed/32775868 http://dx.doi.org/10.1021/acsomega.0c01323 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Hajalsiddig, Tawassl T. H.
Osman, Abu Baker M.
Saeed, Ahmed E. M.
2D-QSAR Modeling and Molecular Docking Studies on 1H-Pyrazole-1-carbothioamide Derivatives as EGFR Kinase Inhibitors
title 2D-QSAR Modeling and Molecular Docking Studies on 1H-Pyrazole-1-carbothioamide Derivatives as EGFR Kinase Inhibitors
title_full 2D-QSAR Modeling and Molecular Docking Studies on 1H-Pyrazole-1-carbothioamide Derivatives as EGFR Kinase Inhibitors
title_fullStr 2D-QSAR Modeling and Molecular Docking Studies on 1H-Pyrazole-1-carbothioamide Derivatives as EGFR Kinase Inhibitors
title_full_unstemmed 2D-QSAR Modeling and Molecular Docking Studies on 1H-Pyrazole-1-carbothioamide Derivatives as EGFR Kinase Inhibitors
title_short 2D-QSAR Modeling and Molecular Docking Studies on 1H-Pyrazole-1-carbothioamide Derivatives as EGFR Kinase Inhibitors
title_sort 2d-qsar modeling and molecular docking studies on 1h-pyrazole-1-carbothioamide derivatives as egfr kinase inhibitors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407542/
https://www.ncbi.nlm.nih.gov/pubmed/32775868
http://dx.doi.org/10.1021/acsomega.0c01323
work_keys_str_mv AT hajalsiddigtawasslth 2dqsarmodelingandmoleculardockingstudieson1hpyrazole1carbothioamidederivativesasegfrkinaseinhibitors
AT osmanabubakerm 2dqsarmodelingandmoleculardockingstudieson1hpyrazole1carbothioamidederivativesasegfrkinaseinhibitors
AT saeedahmedem 2dqsarmodelingandmoleculardockingstudieson1hpyrazole1carbothioamidederivativesasegfrkinaseinhibitors